You are here

Self-organizing synthetic human lungs on microchips to fight infection by RSV

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43AI174385-01A1
Agency Tracking Number: R43AI174385
Amount: $300,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIAID
Solicitation Number: PA22-176
Timeline
Solicitation Year: 2022
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-05-22
Award End Date (Contract End Date): 2024-04-30
Small Business Information
320 Park Ave 18th Floor
New York, NY 10022
United States
DUNS: 117525847
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 FRED ETOC
 (646) 407-0494
 fred@rumiscientific.com
Business Contact
 EDWIN ROSADO-OLIVIERI
Phone: (833) 786-4724
Email: eolivieri@rumiscientific.com
Research Institution
N/A
Abstract

Project Summary
RSV is a major global threat that accounts for a significant share of respiratory disease and
mortality among patients at risk. Infection by highly pathogenic RSV results in acute lung injury,
LRTI, and pneumonia-associated complications. As treatments for RSV are very limited in use
and efficacy, the development of physiological models of this disease is key to develop
therapeutics that limit infection by this virus and associated pathology. This proposal will capitalize
on RumiViro’s mini-lung platform that offers inexhaustible access to genetically matched
organotypic human lung tissue to model infection by respiratory viruses. This platform will be
deployed to model RSV infection in physiological lung tissue and identify therapeutics for this
disease at scale. We will first screen a collection of 23,000 compounds of a highly diverse
phenotypic library of bioactive compounds for their ability to mitigate infection by RSV. Hit
candidates will be further validated for their ability to inhibit multiple clinical strains of RSV in mini-
lungs and primary lung tissue ex vivo. This work will have transformative influence for the
subsequent development of therapeutics and will enable further validation of therapeutic
candidates based on drug metabolism, pharmacokinetic analysis, in vivo proof-of-concept and
lead optimization efforts in follow-up Phase 2 studies. This work will provide a highly efficient
framework for the identification and development of RSV therapeutics with the promise of finding
anti-infective therapeutics that mitigate the RSV-induced pathology in patients at risk.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government